Bolt Biotherapeutics Inc. (BOLT)
0.52
-0.01 (-1.74%)
At close: Jan 14, 2025, 3:58 PM
0.51
-0.95%
Pre-market Jan 15, 2025, 07:53 AM EST
undefined% (undefined)
| Bid | 0.5 |
| Market Cap | 19.71M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -1.71 |
| PE Ratio (ttm) | -0.3 |
| Forward PE | n/a |
| Analyst | Hold |
| Ask | 0.51 |
| Volume | 146,629 |
| Avg. Volume (20D) | 160,131 |
| Open | 0.53 |
| Previous Close | 0.53 |
| Day's Range | 0.51 - 0.53 |
| 52-Week Range | 0.47 - 1.56 |
| Beta | undefined |
About BOLT
Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors; BDC-2034, a carcinoembryonic antigen program for col...
Industry Biotechnology
Sector Healthcare
IPO Date Feb 5, 2021
Employees 100
Stock Exchange NASDAQ
Ticker Symbol BOLT
Website https://www.boltbio.com
Analyst Forecast
According to 5 analyst ratings, the average rating for BOLT stock is "Hold." The 12-month stock price forecast is $1.25, which is an increase of 142.72% from the latest price.
Buy 0.00%
Hold 100.00%
Sell 0.00%
Next Earnings Release
Bolt Biotherapeutics Inc. is scheduled to release its earnings on Mar 20, 2025,
during market hours.
Analysts project revenue of $790.00K, reflecting a -62.18% YoY shrinking and earnings per share of -0.38, making a -19.15% decrease YoY.
Analysts project revenue of $790.00K, reflecting a -62.18% YoY shrinking and earnings per share of -0.38, making a -19.15% decrease YoY.
8 months ago ·
Source
-37.12%
Bolt Biotherapeutics shares are trading lower afte...
Unlock content with
Pro Subscription
8 months ago ·
Source
-0.75%
Bolt Biotherapeutics shares are trading lower. The company reported Q1 financial results.
